Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction

  • Bioorg Med Chem Lett. 2014 Apr 15;24(8):1983-6. doi: 10.1016/j.bmcl.2014.02.055.
Weidong Pan  1 Brian R Lahue  2 Yao Ma  2 Latha G Nair  1 Gerald W Shipps Jr  2 Yaolin Wang  1 Ronald Doll  1 Stéphane L Bogen  3
Affiliations
  • 1. Merck Research Laboratories, Early Development and Discovery Sciences, 2015 Galloping Hill Road, Kenilworth, NJ 07033, United States.
  • 2. Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115, United States.
  • 3. Merck Research Laboratories, Early Development and Discovery Sciences, 2015 Galloping Hill Road, Kenilworth, NJ 07033, United States. Electronic address: [email protected].
Abstract

The discovery of 3,3-disubstituted piperidine 1 as novel p53-HDM2 inhibitors prompted us to implement subsequent SAR follow up directed towards piperidine core modifications. Conformational restrictions and further functionalization of the piperidine core were investigated as a strategy to gain additional interactions with HDM2. Substitutions at positions 4, 5 and 6 of the piperidine ring were explored. Although some substitutions were tolerated, no significant improvement in potency was observed compared to 1. Incorporation of an allyl side chain at position 2 provided a drastic improvement in binding potency.

Keywords
Cancer; HDM2; Protein–protein interaction; p53.